Background Guideline recommendations for chronic obstructive pulmonary disease (COPD) are based on the results of large pharmaceutically-sponsored COPD studies (LPCS). There is a paucity of data on disease characteristics at the primary care level, while the majority of COPD patients are treated in primary care. Objective We aimed to evaluate the external validity of six LPCS (ISOLDE, TRISTAN, TORCH, UPLIFT, ECLIPSE, POET-COPD) on which current guidelines are based, in relation to primary care COPD patients, in order to inform future clinical practice guidelines and trials. Methods Baseline data of seven primary care databases (n = 3508) from Europe were compared to baseline data of the LPCS. In addition, we examined the proportion of primary care patients eligible to participate in the LPCS, based on inclusion criteria. Results Overall, patients included in the LPCS were younger (mean difference (MD)-2.4; p = 0.03), predominantly male (MD 12.4; p = 0.1) with worse lung function (FEV1% MD -16.4; p<0.01) and worse quality of life scores (SGRQ MD 15.8; p = 0.01). There were large differences in GOLD stage distribution compared to primary care patients. Mean exacerbation rates were higher in LPCS, with an overrepresentation of patients with ≥1 and ≥2 exacerbations, although results were not statistically significant. Our findings add to the literature, as we revealed hitherto unknown GOLD I exacerbation characteristics, showing 34% of mild patients had ≥1 exacerbations per year and 12% had ≥2 exacerbations per year. The proportion of primary care patients eligible for inclusion in LPCS ranged from 17% (TRISTAN) to 42% (ECLIPSE, UPLIFT). Conclusion Primary care COPD patients stand out from patients enrolled in LPCS in terms of gender, lung function, quality of life and exacerbations. More research is needed to determine the effect of pharmacological treatment in mild to moderate patients. We encourage future guideline makers to involve primary care populations in their recommendations.
References
[1]
Pierson DJ (2006) Clinical practice guidelines for chronic obstructive pulmonary disease: a review and comparison of current resources. Respiratory Care 51: 277–288.
[2]
Glaab T, Banik N, Rutschmann OT, Wencker M (2006) National survey of guideline-compliant COPD management among pneumologists and primary care physicians. COPD 3: 141–148. doi: 10.1080/15412550600829299
[3]
Aisanov Z, Bai C, Bauerle O, Colodenco FD, Feldman C, et al. (2012) Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world. Int J Chron Obstruct Pulmon Dis 7: 271–282 10.2147/COPD.S28059 [doi];copd-7-271 [pii]. doi: 10.2147/copd.s28059
[4]
Salinas GD, Williamson JC, Kalhan R, Thomashow B, Scheckermann JL, et al. (2011) Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians. Int J Chron Obstruct Pulmon Dis 6: 171–179 10.2147/COPD.S16396 [doi].
[5]
Herland K, Akselsen JP, Skjonsberg OH, Bjermer L (2005) How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med 99: 11–19.
[6]
Travers J, Marsh S, Caldwell B, Williams M, Aldington S, et al. (2007) External validity of randomized controlled trials in COPD. Respir Med 101: 1313–1320 S0954-6111(06)00508-7 [pii];10.1016/j.rmed.2006.10.011 [doi]. doi: 10.1016/j.rmed.2006.10.011
[7]
Rothwell PM (2006) Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials 1: e9 10.1371/journal.pctr.0010009 [doi].
[8]
Global Initiative for Chronic Obstructive Lung Disease (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: http://www.goldcopd.org/. Accessed 2012 Dec 31.
[9]
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, et al. (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320: 1297–1303. doi: 10.1136/bmj.320.7245.1297
[10]
Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, et al. (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361: 449–456 S0140-6736(03)12459-2 [pii];10.1016/S0140-6736(03)12459-2 [doi]. doi: 10.1016/s0140-6736(03)12459-2
[11]
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775–789 356/8/775 [pii];10.1056/NEJMoa063070 [doi]. doi: 10.1056/nejmoa063070
[12]
Decramer M, Celli B, Kesten S, Lystig T, Mehra S, et al. (2009) Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 374: 1171–1178 S0140-6736(09)61298-8 [pii];10.1016/S0140-6736(09)61298-8 [doi]. doi: 10.1016/s0140-6736(09)61298-8
[13]
Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, et al. (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363: 1128–1138 10.1056/NEJMoa0909883 [doi].
[14]
Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, et al. (2011) Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364: 1093–1103 10.1056/NEJMoa1008378 [doi].
[15]
Chavannes N, Stallberg B, Lisspers K, Roman M, Moran A, et al. (2010) UNLOCK: Uncovering and Noting Long-term Outcomes in COPD to enhance knowledge. Prim Care Respir J 19: 408 RHI-046-10 [pii];10.4104/pcrj.2010.00084 [doi]. doi: 10.4104/pcrj.2010.00084
[16]
Jones RC, Dickson-Spillmann M, Mather MJ, Marks D, Shackell BS (2008) Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respir Res 9: 62 1465-9921-9-62 [pii];10.1186/1465-9921-9-62 [doi]. doi: 10.1186/1465-9921-9-62
[17]
Chavannes NH, Grijsen M, van den Akker M, Schepers H, Nijdam M, et al. (2009) Integrated disease management improves one-year quality of life in primary care COPD patients: a controlled clinical trial. Prim Care Respir J 18: 171–176 pcrj-2008-06-0067 [pii];10.3132/pcrj.2009.00003 [doi]. doi: 10.3132/pcrj.2009.00003
[18]
Kruis AL, Boland MR, Schoonvelde CH, Assendelft WJ, Molken MP, et al. (2013) RECODE: Design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care. BMC Pulm Med 13: 17 1471-2466-13-17 [pii];10.1186/1471-2466-13-17 [doi]. doi: 10.1186/1471-2466-13-17
[19]
Kocks J, de Jong C, Berger MY, Kerstjens HA, van der Molen T (2013) Putting health status guided COPD management to the test: protocol of the MARCH study. BMC Pulm Med 13: 41 1471-2466-13-41 [pii];10.1186/1471-2466-13-41 [doi]. doi: 10.1186/1471-2466-13-41
[20]
Tsiligianni IG, van der Molen T, Moraitaki D, Lopez I, Kocks JW, et al. (2012) Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ). BMC Pulm Med 12: 20 1471-2466-12-20 [pii];10.1186/1471-2466-12-20 [doi]. doi: 10.1186/1471-2466-12-20
Sundh J, Janson C, Lisspers K, Stallberg B, Montgomery S (2012) The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD. Prim Care Respir J 21: 295–301 pcrj-2012-04-0066 [pii];10.4104/pcrj.2012.00054 [doi]. doi: 10.4104/pcrj.2012.00054
[23]
Dutch CCMO guidelines.(2013) Available from: http://www.ccmo-online.nl/main.asp?pid=1？&taal=1. Accessed Jan 31 2014.
[24]
Spencer S, Calverley PM, Burge PS, Jones PW (2004) Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 23: 698–702. doi: 10.1183/09031936.04.00121404
[25]
Jones PW, Willits LR, Burge PS, Calverley PM (2003) Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 21: 68–73. doi: 10.1183/09031936.03.00013303
[26]
Celli B, Vestbo J, Jenkins CR, Jones PW, Ferguson GT, et al. (2011) Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med 183: 317–322 201004-0665OC [pii];10.1164/rccm.201004-0665OC [doi]. doi: 10.1164/rccm.201004-0665oc
[27]
Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, et al. (2008) Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178: 332–338 200712-1869OC [pii];10.1164/rccm.200712-1869OC [doi]. doi: 10.1164/rccm.200712-1869oc
[28]
Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, et al. (2009) Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 10: 59 1465-9921-10-59 [pii];10.1186/1465-9921-10-59 [doi]. doi: 10.1186/1465-9921-10-59
[29]
Vestbo J (2004) TORCH study group (2004) The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 24: 206–210. doi: 10.1183/09031936.04.00120603
[30]
Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, et al. (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359: 1543–1554 NEJMoa0805800 [pii];10.1056/NEJMoa0805800 [doi]. doi: 10.1056/nejmoa0805800
[31]
Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, et al. (2010) Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 11: 122 1465-9921-11-122 [pii];10.1186/1465-9921-11-122 [doi].
[32]
Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, et al. (2008) Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 31: 869–873 09031936.00111707 [pii];10.1183/09031936.00111707 [doi]. doi: 10.1183/09031936.00111707
[33]
Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, et al. (1999) Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54: 581–586. doi: 10.1136/thx.54.7.581
[34]
Jones PW, Quirk FH, Baveystock CM (1991) The St George's Respiratory Questionnaire. Respir Med 85 Suppl B: 25–31.
[35]
van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, et al. (2003) Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 1: 13. doi: 10.1186/1477-7525-1-13
[36]
Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, et al. (2005) Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 366: 1875–1881 S0140-6736(05)67632-5 [pii];10.1016/S0140-6736(05)67632-5 [doi]. doi: 10.1016/s0140-6736(05)67632-5
[37]
Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, et al. (2007) International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370: 741–750 S0140-6736(07)61377-4 [pii];10.1016/S0140-6736(07)61377-4 [doi]. doi: 10.1016/s0140-6736(07)61377-4
[38]
Rabe KF, Wedzicha JA (2011) Controversies in treatment of chronic obstructive pulmonary disease. Lancet 378: 1038–1047 S0140-6736(11)61295-6 [pii];10.1016/S0140-6736(11)61295-6 [doi]. doi: 10.1016/s0140-6736(11)61295-6
[39]
Miravitlles M, de la Roza C, Naberan K, Lamban M, Gobartt E, et al. (2007) Use of spirometry and patterns of prescribing in COPD in primary care. Respir Med 101: 1753–1760 S0954-6111(07)00096-0 [pii];10.1016/j.rmed.2007.02.019 [doi]. doi: 10.1016/j.rmed.2007.02.019
[40]
Bourbeau J, Sebaldt RJ, Day A, Bouchard J, Kaplan A, et al. (2008) Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J 15: 13–19.
[41]
White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP (2013) Overtreatment of COPD with inhaled corticosteroids—implications for safety and costs: cross-sectional observational study. PLoS One 8: e75221 10.1371/journal.pone.0075221 [doi];PONE-D-13-09654 [pii]. doi: 10.1371/journal.pone.0075221
[42]
de Miguel-Diez J, Carrasco-Garrido P, Rejas-Gutierrez J, Martin-Centeno A, Gobartt-Vazquez E, et al. (2011) Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status. Lung 189: 199–206 10.1007/s00408-011-9289-0 [doi].
[43]
Kim AM, Tingen CM, Woodruff TK (2010) Sex bias in trials and treatment must end. Nature 465: 688–689 465688a [pii];10.1038/465688a [doi]. doi: 10.1038/465688a
